




**Uscom**

## ASX Media Release

### Appendix 4C Commentary Cash sales up 112% Cash receipts \$1m Quarter ended 31 March 2016

**Sydney, Australia: 12th April 2016:** Uscom (ASX code: UCM) (the **Company** or **Uscom**), a revenue stage, cardiovascular and pulmonary health technology company, today released to market the Appendix 4C for the quarter ended 31 March 2016.

### UCM Quarterly Cash Sales



### Quarterly Financials

- Total cash receipts for quarter \$1m.
- 112% increase in R&D corrected quarterly cash sales; up to \$0.64m from \$0.3m in 2015.
- 83% increase in R&D corrected cash receipts for the first 9 months of the financial year 2016; up to \$1.87m from \$1.02m in 2015.
- Net operating cash outflow \$55k, reduced from 395k in 2015.
- 68% increase in cash on hand; up to \$1m from \$0.6m at March 2015.
- \$0.37m R&D payment received on 3<sup>rd</sup> March 2016.

Uscom CEO Associate Professor Rob Phillips said, *“Our operations continue to strengthen, and while we expect sales to remain lumpy, the trend looks poised to continue. We look forward to closing out this year of transition successfully, and then sustain our revenue growth as the new BP+ and SpiroSonic devices reach market.”*



**Uscom**

## ASX Media Release

---

### About Uscom

Uscom Limited (UCM) is an ASX listed innovative medical technology company specialising in development and marketing of premium cardiovascular and pulmonary medical devices. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A, Uscom BP+ and the Uscom SpiroSonic spirometers. All Uscom devices are premium resolution, and deploy innovative and practice leading technologies with FDA, CE, CFDA and TGA regulatory approval, and which are currently being marketed into global distribution networks.

The USCOM 1A is a simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotrope and vasoactive cardiovascular therapy.

The Uscom BP+ is a supra-systolic oscillometric Central Blood Pressure monitor which measures blood pressure and blood pressure waveforms only previously available using cardiac catheterisation. The Uscom BP+ replaces conventional and more widespread sub-systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension, heart failure, intensive care, general practice and home care.

Uscom SpiroSonic digital ultrasonic spirometers are high fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They are simple and accurate to use and provide research quality pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices are specialised for assessment of COPD, sleep disordered breathing, asthma, industrial diseases and monitoring of pulmonary therapeutic compliance.

For more information, please visit: [www.uscom.com.au](http://www.uscom.com.au)

### Uscom Contacts

**Associate Professor Rob Phillips**  
**Executive Chairman**  
[rob@uscom.com.au](mailto:rob@uscom.com.au)

**Catherine Officer**  
**Company Secretary**  
[secretary@uscom.com.au](mailto:secretary@uscom.com.au)

# Appendix 4C

## Quarterly report for entities admitted on the basis of commitments

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10

Name of entity

**USCOM LIMITED**

ABN

**35 091 028 090**

Quarter ended ("current quarter")

**31 March 2016**

### Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter \$A	Year to date (9 months) \$A
1.1 Receipts from customers	638,059	1,873,329
1.2 Payments for		
(a) staff costs	(361,721)	(1,047,362)
(b) advertising and marketing	(159,658)	(593,337)
(c) research and development	(155,204)	(416,172)
(d) leased assets	-	-
(e) other working capital	(385,393)	(1,071,886)
1.3 Dividends received	-	-
1.4 Interest and other items of a similar nature received	1,951	9,831
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes refund	-	-
1.7 Other (R&D Tax Incentive Grant)	366,831	361,872
<b>Net operating cash flows</b>	<b>(55,135)</b>	<b>(883,725)</b>

**Appendix 4C**  
**Quarterly report for entities**  
**admitted on the basis of commitments**

	Current quarter \$A	Year to date (9.months) \$A
1.8 Net operating cash flows (carried forward)	<b>(55,135)</b>	<b>(883,725)</b>
<b>Cash flows related to investing activities</b>		
1.9 Payment for acquisition of:		
(a) businesses (item 5)	-	(592,920)
(b) equity investments	-	-
(c) intellectual property	(7,973)	(66,641)
(d) physical non-current assets	-	(3,567)
(e) other non-current assets	-	-
1.10 Proceeds from disposal of:		
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	-
(e) other non-current assets	-	-
1.11 Loans to other entities	-	-
1.12 Loans repaid by other entities	-	-
1.13 Other (provide details if material)	(2,582)	(2,582)
<b>Net investing cash flows</b>	<b>(10,555)</b>	<b>(665,710)</b>
<b>1.14 Total operating and investing cash flows</b>	<b>(65,690)</b>	<b>(1,549,435)</b>
<b>Cash flows related to financing activities</b>		
1.15 Proceeds from issues of shares, options, etc.	4,463	2,148,961
1.16 Proceeds from sale of forfeited shares	-	-
1.17 Proceeds from borrowings	-	-
1.18 Repayment of borrowings	-	-
1.19 Dividends paid	-	-
1.20 Other (provide details if material)	-	-
Private placement proceeds received in advance	-	-
Share issued costs	-	-
	(1,654)	(119,192)
<b>Net financing cash flows</b>	<b>2,809</b>	<b>2,029,769</b>
<b>Net increase (decrease) in cash held</b>	<b>(62,881)</b>	<b>480,334</b>
1.21 Cash at beginning of quarter/year to date	<b>1,069,532</b>	526,317
1.22 Exchange rate adjustments to item 1.20	-	-
1.23 <b>Cash at end of quarter</b>	<b>1,006,651</b>	<b>1,006,651</b>

**Payments to directors of the entity and associates of the directors**

**Payments to related entities of the entity and associates of the related entities**

		Current quarter \$A
1.24	Aggregate amount of payments to the parties included in item 1.2	123,735
1.25	Aggregate amount of loans to the parties included in item 1.11	NIL

1.26 Explanation necessary for an understanding of the transactions

N/A

**Non-cash financing and investing activities**

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

**Financing facilities available**

*Add notes as necessary for an understanding of the position.*

		Amount available \$A	Amount used \$A
3.1	Loan facilities	NIL	NIL
3.2	Credit standby arrangements	NIL	NIL



## Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report except for any additional disclosure requirements requested by AASB 107 that are not already itemised in this report.
3. **Accounting Standards.** ASX will accept, for example, the use of International Financial Reporting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.